Abstract
FAM134B is a putative tumour suppressor gene and no mutations in FAM134B have been reported in colorectal cancer (CRC) to date. This study aims to identify FAM134B mutation sites and the clinicopathological significance of the gene in patients with CRC. Eighty-eight colorectal cancers were studied for FAM134B mutations by Sanger sequencing. The mutations in these cancers were then tested for correlations with the clinical and pathological parameters of the studied cancers. In addition, mRNA and protein expression of FAM134B in colorectal cancers was examined by polymerase chain reaction, Western blots, and immunofluorescence analysis. FAM134B mutation was noted in 46.5% (41/88) of patients with CRC. Thirty-one novel potentially pathogenic mutations were noted in coding and intronic regions of FAM134B in CRC, the majority of which were single-nucleotide substitutions. Of the 31 mutations, eight novel frameshift mutations showed potential to cause non-sense-mediated mRNA decay (NMD) in computational analysis. In addition, FAM134B mutations were associated with various clinical and pathological variables, including sex of the patients, presence of metachronous cancer, size, T staging, presence of distant metastases, and positivity of microsatellite instability (MSI) in the cancer (p < 0.05). FAM134B mRNA and protein expression was decreased in FAM134B mutated cancers. To conclude, FAM134B mutation is common in colorectal cancer. The association of the mutation of this gene with adverse clinical and pathological parameters is congruent with the tumour suppressive properties of the gene.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alqurashi N, Gopalan V, Smith RA, Lam AK (2013) Clinical impacts of mammalian target of rapamycin expression in human colorectal cancers. Hum Pathol 44:2089–2096
Buchholz TA, Weil MM, Story MD, Strom EA, Brock WA, McNeese MD (1999) Tumor suppressor genes and breast cancer. Radiat Oncol Investig 7:55–65
Chiramel AI, Dougherty JD, Nair V, Robertson SJ, Best SM (2016) FAM134B, the selective autophagy receptor for endoplasmic reticulum turnover, inhibits replication of Ebola virus strains Makona and Mayinga. J Infect Dis 214:s319–s325
Davidson G, Murphy S, Polke J, Laura M, Salih M, Muntoni F, Blake J, Brandner S, Davies N, Horvath R, Price S, Donaghy M, Roberts M, Foulds N, Ramdharry G, Soler D, Lunn M, Manji H, Davis M, Houlden H, Reilly M (2012) Frequency of mutations in the genes associated with hereditary sensory and autonomic neuropathy in a UK cohort. J Neurol 259:1673–1685
Gopalan V, Smith RA, Nassiri MR, Yasuda K, Salajegheh A, Kim SY, Ho YH, Weinstein S, Tang JC, Lam AK (2010) GAEC1 and colorectal cancer: a study of the relationships between a novel oncogene and clinicopathologic features. Hum Pathol 41:1009–1015
Hamilton SR, Bosman FT, Boffetta P, Ilas M, Morreau H, Nakamura SI, Quirke P, Riboli E, Sobin LH (2010) Carcinoma of the colon and rectum. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds) WHO classification of tumors of the digestive system. IARC Press, Lyon, pp 134–146
Haque MH, Gopalan V, Chan KW, Shiddiky MJ, Smith RA, Lam AK (2016) Identification of novel FAM134B (JK1) mutations in oesophageal squamous cell carcinoma. Sci Rep 6:29173
Ilgaz AE, Rolfs A, Serteser M, Parman Y (2014) Mutation in FAM134B causing hereditary sensory neuropathy with spasticity in a Turkish family. Muscle Nerve 49:774–775
Islam F, Gopalan V, Wahab R, Smith RA, Qiao B, Lam AK (2017) Stage dependent expression and tumor suppressive function of FAM134B (JK1) in colon cancer. Mol Carcinog 56:238–249
Kasem K, Gopalan V, Salajegheh A, Lu CT, Smith RA, Lam AK (2014a) The roles of JK-1 (FAM134B) expressions in colorectal cancer. Exp Cell Res 326:166–173
Kasem K, Sullivan E, Gopalan V, Salajegheh A, Smith RA, Lam AK (2014b) FAM134B (FAM134B) represses cell migration in colon cancer: a functional study of a novel gene. Exp Mol Pathol 97:99–104
Kasem K, Gopalan V, Salajegheh A, Lu CT, Smith RA, Lam AK (2014c) FAM134B (FAM134B) gene and colorectal cancer: a pilot study on the gene copy number alterations and correlations with clinicopathological parameters. Exp Mol Pathol 97:31–36
Khaminets A, Heinrich T, Mari M, Grumati P, Huebner AK, Akutsu M, Liebmann L, Stolz A, Nietzsche S, Koch N, Mauthe M, Katona I, Qualmann B, Weis J, Reggiori F, Kurth I, Hübner CA, Dikic I (2015) Regulation of endoplasmic reticulum turnover by selective autophagy. Nature 522:354–358
Kong M, Kim Y, Lee C (2011) A strong synergistic epistasis between FAM134B and TNFRSF19 on the susceptibility to vascular dementia. Psychiatr Genet 21:37–41
Kurth I, Pamminger T, Hennings JC, Soehendra D, Huebner AK, Rotthier A, Baets J, Senderek J, Topaloglu H, Farrell SA, Nürnberg G, Nürnberg P, De Jonghe P, Gal A, Kaether C, Timmerman V, Hübner CA (2009) Mutations in FAM134B, encoding a newly identified Golgi protein, cause severe sensory and autonomic neuropathy. Nat Genet 41:1179–1181
Lai H, Lin L, Nadji M, Lai S, Trapido E, Meng L (2002) Mutations in the p53 tumor suppressor gene and early onset breast cancer. Cancer Biol Ther 1:31–36
Lam AK, Ong K, Giv MJ, Ho YH (2008a) p16 expression in colorectal adenocarcinoma: marker of aggressiveness and morphological types. Pathology 40:580–585
Lam AK, Ong K, Ho YH (2008b) Aurora kinase expression in colorectal adenocarcinoma: correlations with clinicopathological features, p16 expression, and telomerase activity. Hum Pathol 39:599–604
Lam AK, Gopalan V, Nassiri MR, Kasim K, Dissanayake J, Tang JC, Smith RA (2011) Altered JS-2 expression in colorectal cancers and its clinical pathological relevance. Mol Oncol 5:475–481
Lam AK, Gopalan V, Carmichael R, Buettner PG, Leung M, Smith R, Lu CT, Ho YH, Siu S (2012) Metachronous carcinomas in colorectum and its clinicopathological significance. Int J Colorectal Dis 27:1303–1310
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods 25:402–408
Melchiotti R, Puan KJ, Andiappan AK, Poh TY, Starke M, Zhuang L, Petsch K, Lai TS, Chew FT, Larbi A, de Wang Y, Poidinger M, Rotzschke O (2014) Genetic analysis of an allergic rhinitis cohort reveals an intercellular epistasis between FAM134B and CD39. BMC Med Genet 15:73
Murphy SM, Davidson GL, Brandner S, Houlden H, Reilly MM (2012) Mutation in FAM134B causing severe hereditary sensory neuropathy. J Neurol Neurosurg Psychiatry 83:119–120
Pakneshan S, Salajegheh A, Smith RA, Lam AK (2013) Clinicopathological relevance of BRAF mutations in human cancer. Pathology 45:346–356
Pritchard CC, Grady WM (2011) Colorectal cancer molecular biology moves into clinical practice. Gut 60:116–129
Rahman MA, Salajegheh A, Smith RA, Lam AK (2013) B-Raf mutation: a key player in molecular biology of cancer. Exp Mol Pathol 95:336–342
Rahman MA, Salajegheh A, Smith RA, Lam AK (2014) BRAF inhibitor therapy for melanoma, thyroid and colorectal cancers: development of resistance and future prospects. Curr Cancer Drug Targets 14:128–143
Rahman MA, Salajegheh A, Smith RA, Lam AK (2015a) MicroRNA-126 suppresses proliferation of undifferentiated (BRAF(V600E) and BRAF(WT)) thyroid carcinoma through targeting PIK3R2 gene and repressing PI3K-AKT proliferation-survival signalling pathway. Exp Cell Res 339:342–350
Rahman MA, Salajegheh A, Smith RA, Lam AK (2015b) Multiple proliferation-survival signalling pathways are simultaneously active in BRAF V600E mutated thyroid carcinomas. Exp Mol Pathol 99:492–497
Rahman MA, Salajegheh A, Smith RA, Lam AK (2016) Inhibition of BRAF kinase suppresses cellular proliferation, but not enough for complete growth arrest in BRAF V600E mutated papillary and undifferentiated thyroid carcinomas. Endocrine 54:129–138
Rivera MN, Kim WJ, Wells J, Driscoll DR, Brannigan BW, Han M, Kim JC, Feinberg AP, Gerald WL, Vargas SO, Chin L, Iafrate AJ, Bell DW, Haber DA (2007) An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science 315:642–645
Saleh S, Lam AK, Ho YH (2008) Real-time PCR quantification of human telomerase reverse transcriptase (hTERT) in colorectal cancer. Pathology 40:25–30
Schwarz JM, Cooper DN, Schuelke M, Seelow D (2014) MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods 11:361–362
Tang JC, Lam KY, Law S, Wong J, Srivastava G (2001) Detection of genetic alterations in esophageal squamous cell carcinomas and adjacent normal epithelia by comparative DNA fingerprinting using inter-simple sequence repeat PCR. Clin Cancer Res 7:1539–1545
Tang WK, Chui CH, Fatima S, Kok SH, Pak KC, Ou TM, Hui KS, Wong MM, Wong J, Law S, Tsao SW, Lam KY, Beh PS, Srivastava G, Chan AS, Ho KP, Tang JC (2007) Oncogenic properties of a novel gene JK-1 located in chromosome 5p and its overexpression in human esophageal squamous cell carcinoma. Int J Mol Med 19:915–923
Acknowledgements
The project was supported by the student scholarship from Griffith University and funding from Menzies Health Institute Queensland.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
There is no conflict of interest in publishing this paper.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Islam, F., Gopalan, V., Wahab, R. et al. Novel FAM134B mutations and their clinicopathological significance in colorectal cancer. Hum Genet 136, 321–337 (2017). https://doi.org/10.1007/s00439-017-1760-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00439-017-1760-4